• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Hydroxyurea: a new old therapy for Langerhans cell histiocytosis.羟基脲：一种用于朗格汉斯细胞组织细胞增多症的新的旧疗法。
Blood. 2016 Nov 17;128(20):2462-2465. doi: 10.1182/blood-2016-06-721993. Epub 2016 Sep 29.
2
Methotrexate and cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis: A single arm, single center, prospective phase 2 study.甲氨蝶呤和阿糖胞苷治疗新诊断的成人朗格汉斯细胞组织细胞增多症：一项单臂、单中心、前瞻性2期研究。
Am J Hematol. 2020 Sep;95(9):E235-E238. doi: 10.1002/ajh.25864. Epub 2020 Jun 20.
3
Intensification of induction therapy and prolongation of maintenance therapy did not improve the outcome of pediatric Langerhans cell histiocytosis with single-system multifocal bone lesions: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.强化诱导治疗和延长维持治疗并未改善单系统多灶性骨病变的儿童朗格汉斯细胞组织细胞增生症的结局：日本朗格汉斯细胞组织细胞增生症研究组-02 方案研究的结果。
Int J Hematol. 2018 Aug;108(2):192-198. doi: 10.1007/s12185-018-2444-0. Epub 2018 Mar 28.
4
Langerhans cell histiocytosis: a 16-year experience.朗格汉斯细胞组织细胞增多症：16年经验总结
J Pediatr (Rio J). 2007 Jan-Feb;83(1):79-86. doi: 10.2223/JPED.1581. Epub 2007 Jan 23.
5
[Langerhans cell histiocytosis of the temporal bone: 22 cases analysis].[颞骨朗格汉斯细胞组织细胞增多症：22例分析]
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2010 Mar;45(3):212-6.
6
Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.由阿糖胞苷、长春新碱和泼尼松龙组成的强化延长治疗可改善多系统朗格汉斯细胞组织细胞增多症患者的预后：日本朗格汉斯细胞组织细胞增多症研究组-02方案研究结果
Int J Hematol. 2016 Jul;104(1):99-109. doi: 10.1007/s12185-016-1993-3. Epub 2016 Apr 4.
7
Prognostic criteria, treatment and survival in disseminated histiocytosis X.播散性组织细胞增多症X的预后标准、治疗与生存情况
Aust Paediatr J. 1979 Jun;15(2):91-5. doi: 10.1111/j.1440-1754.1979.tb01196.x.
8
Nationwide survey of bisphosphonate therapy for children with reactivated Langerhans cell histiocytosis in Japan.日本全国范围内针对朗格汉斯细胞组织细胞增生症患儿进行双磷酸盐治疗的调查。
Pediatr Blood Cancer. 2011 Jan;56(1):110-5. doi: 10.1002/pbc.22703.
9
Outcome of children with Langerhans cell histiocytosis and single-system involvement: A retrospective study at a single center in Shanghai, China.朗格汉斯细胞组织细胞增多症单系统受累患儿的预后：中国上海某单中心的回顾性研究
Pediatr Hematol Oncol. 2018 Oct-Nov;35(7-8):385-392. doi: 10.1080/08880018.2018.1545814. Epub 2019 Jan 29.
10
Outcome of High-risk Langerhans Cell Histiocytosis (LCH) in Egyptian Children, Does Intermediate-dose Methotrexate Improve the Outcome?埃及儿童高危朗格汉斯细胞组织细胞增多症（LCH）的预后，中等剂量甲氨蝶呤能否改善预后？
J Pediatr Hematol Oncol. 2019 Nov;41(8):635-643. doi: 10.1097/MPH.0000000000001314.

引用本文的文献

1
Current State of Targeted Therapy in Adult Langerhans Cell Histiocytosis and Erdheim-Chester Disease.成人朗格汉斯细胞组织细胞增生症和 Erdheim-Chester 病的靶向治疗现状。
Target Oncol. 2024 Sep;19(5):691-703. doi: 10.1007/s11523-024-01080-x. Epub 2024 Jul 11.
2
Orbital histiocytosis; From A to Z.眼眶组织细胞增生症；从 A 到 Z。
Int Ophthalmol. 2024 Jun 20;44(1):236. doi: 10.1007/s10792-024-03179-6.
3
Langerhans cell histiocytosis: NACHO update on progress, chaos, and opportunity on the path to rational cures.朗格汉斯细胞组织细胞增生症：NACHO 对进展、混乱和理性治疗之路的机会的更新。
Cancer. 2024 Jul 15;130(14):2416-2439. doi: 10.1002/cncr.35301. Epub 2024 Apr 30.
4
Vulvar Langerhans cell histiocytosis: Clinicopathologic characteristics, mutational profile, and treatment of 4 patients in a single-center cohort.外阴朗格汉斯细胞组织细胞增多症：单中心队列中4例患者的临床病理特征、突变谱及治疗情况
JAAD Case Rep. 2023 Apr 23;36:78-81. doi: 10.1016/j.jdcr.2023.03.024. eCollection 2023 Jun.
5
International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults.国际专家共识建议：成人朗格汉斯细胞组织细胞增生症的诊断与治疗。
Blood. 2022 Apr 28;139(17):2601-2621. doi: 10.1182/blood.2021014343.
6
Histiocytic disorders.组织细胞增生症。
Nat Rev Dis Primers. 2021 Oct 7;7(1):73. doi: 10.1038/s41572-021-00307-9.
7
Multifocal Langerhans Cell Histiocytosis: A Unique Presentation of Eosinophilic Granuloma with Intracranial Extension, Massive Lymphadenopathy, and Epstein-Barr Viral Infection in an Adolescent Female.多灶性朗格汉斯细胞组织细胞增多症：一名青春期女性嗜酸性肉芽肿伴颅内扩展、巨大淋巴结病及爱泼斯坦-巴尔病毒感染的独特表现
Case Rep Dermatol. 2021 Jan 25;13(1):28-35. doi: 10.1159/000511488. eCollection 2021 Jan-Apr.
8
Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease.组织细胞疾病：对朗格汉斯细胞组织细胞增生症和 Erdheim-Chester 病新型生物学的深入了解及其对治疗的影响。
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):395-399. doi: 10.1182/hematology.2020000159.
9
Isolated Cutaneous Langerhans Cell Histiocytosis Presenting in an Adult Male.一名成年男性出现的孤立性皮肤朗格汉斯细胞组织细胞增多症
Cureus. 2020 Aug 19;12(8):e9861. doi: 10.7759/cureus.9861.
10
Langerhans cell histiocytosis in adults: Advances in pathophysiology and treatment.成人朗格汉斯细胞组织细胞增生症：病理生理学和治疗进展。
Cancer Sci. 2018 Dec;109(12):3707-3713. doi: 10.1111/cas.13817. Epub 2018 Oct 30.

本文引用的文献

1
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages.巨噬细胞-树突状细胞谱系组织细胞增多症和肿瘤的修订分类
Blood. 2016 Jun 2;127(22):2672-81. doi: 10.1182/blood-2016-01-690636. Epub 2016 Mar 10.
2
Langerhans Cell Histiocytosis: Emerging Insights and Clinical Implications.朗格汉斯细胞组织细胞增多症：新见解与临床意义
Oncology (Williston Park). 2016 Feb;30(2):122-32, 139.
3
Differentiating skin-limited and multisystem Langerhans cell histiocytosis.鉴别皮肤局限性和多系统朗格汉斯细胞组织细胞增多症。
J Pediatr. 2014 Nov;165(5):990-6. doi: 10.1016/j.jpeds.2014.07.063. Epub 2014 Oct 21.
4
Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.MAP2K1和BRAF中相互排斥的复发性体细胞突变支持ERK激活在朗格汉斯细胞组织细胞增生症（LCH）发病机制中起核心作用。
Blood. 2014 Nov 6;124(19):3007-15. doi: 10.1182/blood-2014-05-577825. Epub 2014 Sep 8.
5
High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.肢端肥大细胞组织细胞增生症中 BRAF V600E 阴性患者存在高频率的体细胞 MAP2K1 突变。
Blood. 2014 Sep 4;124(10):1655-8. doi: 10.1182/blood-2014-05-577361. Epub 2014 Jun 30.
6
BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.前体细胞与分化树突状细胞中 BRAF-V600E 的表达定义了具有临床显著差异的 LCH 危险分组。
J Exp Med. 2014 Apr 7;211(4):669-83. doi: 10.1084/jem.20130977. Epub 2014 Mar 17.
7
Pathological consequence of misguided dendritic cell differentiation in histiocytic diseases.组织细胞疾病中树突状细胞分化错误的病理后果。
Adv Immunol. 2013;120:127-61. doi: 10.1016/B978-0-12-417028-5.00005-3.
8
The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.欧洲药品管理局对 vemurafenib（Zelboraf®）治疗 BRAF V600 突变阳性不可切除或转移性黑色素瘤的成人患者的审查：人用药品委员会对科学评估的总结。
Eur J Cancer. 2013 May;49(7):1654-61. doi: 10.1016/j.ejca.2013.01.015. Epub 2013 Mar 5.
9
Notch is active in Langerhans cell histiocytosis and confers pathognomonic features on dendritic cells.Notch 在朗格汉斯细胞组织细胞增生症中呈活跃状态，并赋予树突状细胞特征性表现。
Blood. 2012 Dec 20;120(26):5199-208. doi: 10.1182/blood-2012-02-410241. Epub 2012 Oct 16.
10
Impact of hydroxyurea on clinical events in the BABY HUG trial.BABY HUG 试验中羟基脲对临床事件的影响。
Blood. 2012 Nov 22;120(22):4304-10; quiz 4448. doi: 10.1182/blood-2012-03-419879. Epub 2012 Aug 22.

Hydroxyurea: a new old therapy for Langerhans cell histiocytosis.

作者信息

Zinn Daniel J, Grimes Amanda B, Lin Howard, Eckstein Olive, Allen Carl E, McClain Kenneth L

机构信息

Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, TX.

出版信息

Blood. 2016 Nov 17;128(20):2462-2465. doi: 10.1182/blood-2016-06-721993. Epub 2016 Sep 29.

DOI:10.1182/blood-2016-06-721993
PMID:27688802
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5114488/
Abstract
摘要